Shots:
- Smiths to receive 2.5M at closing in cash and stock which is currently valued at ~$500M, $1.85B in cash along with liabilities & is eligible for up to $100M in milestones. The transaction is expected to close in H1’22
- The acquisition combines Smiths’ business includes syringes, ambulatory infusion devices, vascular access & vital care products with ICU Medical’s existing businesses to create a leading infusion therapy company with a stronger global reach
- The companies have entered into an option agreement in which Smiths has the right to acquire ICU Medical by entering into a binding share purchase agreement. Additionally, Smith will retain ~ 10% of ICU Medical
Click here to read full press release/ article | Ref: Globe Newswire | Image: PharmaLive
The post ICU Medical Commits to Acquire Smith for ~$2.35B first appeared on PharmaShots.
